Management will use the event at Sergelkonferensen to detail how the device, which aims to treat gastroesophageal reflux disease without the common side effects of traditional esophageal wrapping, will compete for market share. The presentation will feature clinical perspectives from surgeons and patient testimonials to support the company’s expansion narrative. Beyond the immediate U.S. launch, the firm plans to showcase its broader pipeline, including wireless energizing platforms and eHealth technologies designed for remote monitoring of internal implants. Investors unable to attend the session in person can access the proceedings via a live webcast starting at 14:00 CEST.
In section Releases
Implantica Sets Sights on U.S. Market Following RefluxStop Approval
With FDA approval of its flagship RefluxStop device now secured, Implantica AG is turning its attention to a massive U.S. market segment where an estimated 78 million people suffer from chronic acid reflux. The company will outline its commercial rollout strategy during a Capital Markets Day in Stockholm on September 9.
Comments (0)
No comments yet. Be the first!